ZLNA ZELLUNA ASA

Zelluna ASA – Ex. date

Zelluna ASA – Ex. date

The shares in Zelluna ASA will from today, 4 November 2025, be traded exclusive of the right to participate in the contemplated subsequent offering announced on 3 November 2025.

This information is published in accordance with the requirements of the Continuing Obligations for Euronext Oslo Børs.



 



EN
04/11/2025

Underlying

ZLNAZELLUNA ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZELLUNA ASA

 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved w...

Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved with CTA Submission Oslo, 12 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents its results for the fourth quarter and full year 2025. Webcast scheduled for 12 February 2026, at 08:30 (CET). Link to webcast . Operational Highlights Q4 2025 CTA submitted: On 17 December 2025, Zelluna submitted its first Clinical Trial Application (CTA) to the UK MHRA for ZI-MA4-1, the world's ...

February 12, 2026 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA: Fjerde kvartal 2025 – Viktig regulatorisk milepæl oppnådd...

Zelluna ASA: Fjerde kvartal 2025 – Viktig regulatorisk milepæl oppnådd med CTA-innlevering Oslo, 12. februar 2026 – Zelluna (OSE: ZLNA), et selskap som utvikler allogene "off-the-shelf" T-cellereseptor-baserte Natural Killer (TCR-NK) celleterapier for behandling av kreft, presenterer i dag resultatene for fjerde kvartal og året 2025. Webcast er planlagt 12. februar 2026 kl. 08:30 (CET). Lenke til webcast . Operasjonelle høydepunkter Q4 2025: CTA innlevert: 17. desember 2025 leverte Zelluna sin første søknad om oppstart av klinisk studie (Clinical Trial Application, CTA) til UK MH...

February 12, 2026 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical tr...

Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial Global CRO to support execution of ZIMA-101 study with world's first MAGE-A4-targeting TCR-NK cell therapy productPartnership follows submission of the Clinical Trial Application (CTA) to the MHRA Oslo, Norway – 11 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced a clinical partnership with Medpace, a leading global Contract Research Organization (CRO), to support the f...

February 11, 2026 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna inngår avtale med Medpace om første kliniske studie – pasientd...

Zelluna inngår avtale med Medpace om første kliniske studie – pasientdata ventes fra medio 2026 Global CRO-partner skal støtte gjennomføring av ZIMA-101 studie med verdens første MAGE-A4-rettede TCR-NK celleterapiproduktAvtalen kommer etter innlevering av søknad om oppstart av klinisk studie (CTA) til britiske legemiddelmyndigheter (MHRA) Oslo, Norge – 11. februar 2026 – Zelluna (OSE: ZLNA), et selskap som utvikler allogen "off-the-shelf" T-cellereseptor-basert Natural Killer (TCR-NK) celleterapi for behandling av kreft, kunngjør i dag en partneravtale med Medpace, en ledende global CRO (C...

February 11, 2026 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA - Grant of Share Options

Zelluna ASA - Grant of Share Options Oslo, 5 February 2026: On the basis of the authorization granted by the General Meeting on 29 April 2025 for the Board of Directors of Zelluna ASA (the “Company”, OSE ticker “ZLNA”) to issue shares to employees and board members under a long-term incentive program, the Board of Directors has resolved to grant share options to two employees in the Company. A total of 75,000 new share options have been granted to two employees. Following these grants, the total number of options outstanding corresponds to 5.5% of the Company’s outstanding share capital. ...

February 5, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch